Torrey Pines Medicine (Shenzhen) Ltd. has completed an angel financing round as it advances next-generation ultralong-acting peptide therapeutics for metabolic diseases.
Ascletis Pharma Inc. has released preclinical data for ASC-37, a next-generation glucagon-like peptide 1 receptor (GLP-1R)/gastric inhibitory polypeptide receptor (GIPR)/glucagon receptor (GCGR) triple peptide agonist.
Ascletis Pharma Inc. has submitted two IND applications to the FDA for ASC-36 once-monthly injection and ASC-36_35 once-monthly injection co-formulation for the treatment of obesity.
Ascletis Pharma Inc. has received IND clearance from the FDA for ASC-35, a once-monthly subcutaneously administered GLP-1 receptor (GLP-1R)/GIP receptor (GIPR) dual peptide agonist, for the treatment of obesity.
Cenna Biosciences Inc. has obtained IND clearance from the FDA for 8M2D, a first-in-class peptide for the treatment of Alzheimer’s disease. A phase Ia/Ib trial of 8M2D in healthy volunteers and patients with early Alzheimer’s disease is expected to begin dosing late this year.
Researchers from Verdiva Bio Ltd. and collaborators recently presented preclinical data on VRB-103, an oral amylin analogue, comparing its profile with those of cagrilintide and eloralintide, two subcutaneously administered analogues currently in clinical development.
Researchers from the University of Copenhagen and collaborating institutions aimed to develop a therapy for chronic neuropathic pain based on gene therapy delivered with adeno-associated viral (AAV) vectors.
Syracuse University recently presented a comprehensive preclinical program describing the rational design and optimization of peptide antagonists targeting the GDF15/GFRAL/RET receptor complex to mitigate nausea, emesis, anorexia and wasting associated with chemotherapy-induced stress signaling.
Pinnacle Medicines Inc. secured $89 million in a series B financing, bringing the total raised by the company to $134 million. The round was co-led by LAV and Foresite Capital.
RSS
